Despite concerns over a bubble and regulation, biotech investing remains very hot for investors. It doesn’t hurt that even with the recent sell-off the space is easily outperforming broad indexes so far in 2015. But with added risks, it might be time for investors to consider an ETF approach to the space so that one company doesn’t blow up a portfolio.

Eric Dutram takes a look at the biotech ETF space and some of the key differences between the most popular funds in the space in this video. He also highlights a few factors that investors must consider when they are deciding which ETF is the best for their biotech investing needs.

SPDR SP Biotech ETF:
iShares NASDAQ Biotechnology Index Fund:
Market Vectors Biotech ETF:
Bioshares Biotechnology Clinical Trials:
Bioshares Biotechnology Products Fund:

Follow us on StockTwits:
Follow us on Twitter:
Like us on Facebook:

Articles You May Like

Fed’s Daly sees interest rates heading beyond neutral level
Coinbase shares fall after rival Binance.US drops spot bitcoin trading fees
Denver Airport gets ratings lift from Moody’s
Harmony hacker sends stolen funds to Tornado Cash mixer
Pending home sales post surprise increase in May, likely due to brief pullback in mortgage rates